Sitryx Therapeutics Limited

Sitryx Therapeutics Limited is a clinical-stage biopharmaceutical company based in Oxford, United Kingdom, focused on immunometabolism — the interface between cellular metabolism and immune function. The company describes itself as developing novel oral therapies intended to restore immune balance in inflammatory disease, moving beyond symptom management toward what it calls lasting, functional cures. Its approach, which it brands as precision immunology, uses oral small-molecule, disease-modifying therapies designed to modulate disease-driving immune cells and target specific pathways that sustain inflammation. Sitryx positions its pipeline as first- and potentially best-in-class therapeutic candidates intended to deliver biologic-like efficacy with improved safety and tolerability. Its lead clinical program is SYX-5219, an oral pyruvate kinase M2 (PKM2) modulator. According to company communications, SYX-5219 has completed a Phase 1a trial evaluating safety, tolerability and pharmacokinetics, where it was reported to be well tolerated and to produce a dose-dependent reduction in serum CCL17/TARC — a key biomarker in atopic dermatitis — with reductions at higher doses described as comparable to those seen with established IL-4/IL-13 biologics. The candidate has advanced into a Phase 1b trial in atopic dermatitis, with a readout expected by year end. Beyond atopic dermatitis, Sitryx has described pipeline programs in psoriasis and asthma. The company has attracted strategic collaborations with global biopharmaceutical companies, which it cites as validation of its innovation and of the market opportunity in multibillion-dollar inflammatory disease indications. One named collaboration is with Boehringer Ingelheim. Sitryx is led by Chief Executive Officer Iain Kilty, with an executive team including Chief Medical Officer Dr. Ravi Rao, Chief Operating Officer Ben Stephens, Chief Financial Officer Adam Mostafa, Senior Vice President of Development Lisa Pierre, and Vice President of People and Organization Fiona Irvine. Its board and scientific advisory network include globally recognized figures from academic immunology and the life-sciences investment community, including Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum, Houman Ashrafian, Kate Bingham, Maina Bhaman, Nikola Trbovic, Brad Robling, Sanne de Jongh, Jeremy Griggs, Rich Aldrich, Neil Weir and board chairman Pierre Legault. Founder Paul-Peter Tak serves as an independent director. As a private company, Sitryx is backed by specialist life-science investors and strategic partners rather than being publicly listed. Its investor and board affiliations include SV Health Investors, Sofinnova, Longwood Fund, Oxford Science Enterprises, Eli Lilly and Company, and GSK. The company's stated mission is to translate immunometabolism science into oral medicines that can achieve sustained disease remission for patients with inflammatory diseases who remain underserved by existing therapies.

Sitryx Therapeutics Limited is a clinical-stage biopharmaceutical company located in Oxford, United Kingdom, working at the intersection of immunology and cellular metabolism — a field it refers to as immunometabolism. The company was founded with the involvement of Paul-Peter Tak, who is identified as Founder and Independent Director, and it has assembled a leadership team and board drawn from academic immunology, drug development and specialist life-science investing. From its outset, Sitryx has pursued oral small-molecule therapies intended to modulate disease-driving immune cells rather than merely suppress symptoms. Its stated scientific premise is that precise modulation of metabolic pathways inside immune cells can rebalance immune function and drive sustained disease remission in inflammatory disease. The company describes its pipeline as comprising first- and potentially best-in-class candidates designed to achieve biologic-like efficacy with improved safety and tolerability. Sitryx's lead clinical program is SYX-5219, an oral pyruvate kinase M2 (PKM2) modulator. In an earlier Phase 1a trial, the company evaluated the safety, tolerability and pharmacokinetics of SYX-5219; according to company communications, the candidate was well tolerated and produced a dose-dependent reduction in serum CCL17/TARC, a key biomarker in atopic dermatitis, with reductions at higher doses characterized as comparable to those seen with established IL-4/IL-13 biologics. The program subsequently advanced into a Phase 1b trial in atopic dermatitis, with a data readout expected by year end. Beyond atopic dermatitis, Sitryx has described pipeline programs in psoriasis and asthma. The company has entered strategic collaborations with global biopharmaceutical companies, which it presents as validation of its innovation and of the market opportunity in multibillion-dollar inflammatory disease indications. One named collaboration is with Boehringer Ingelheim. Sitryx's investor and board network includes SV Health Investors, Sofinnova, Longwood Fund, Oxford Science Enterprises, Eli Lilly and Company and GSK, alongside academic advisors such as Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum. The company is led by CEO Iain Kilty, with an executive team including Chief Medical Officer Dr. Ravi Rao, Chief Operating Officer Ben Stephens, Chief Financial Officer Adam Mostafa, Senior Vice President of Development Lisa Pierre and Vice President of People and Organization Fiona Irvine; Neil Weir serves as President and Pierre Legault as Board Chairman. As a private company, Sitryx is not publicly listed and funds its research and clinical development through private investment and strategic partnerships. Its mission, as stated on its website, is to move beyond alleviating the signs and symptoms of disease to achieve lasting, functional cures for patients with inflammatory diseases.

• Sitryx Therapeutics founded with Paul-Peter Tak as Founder and Independent Director

• Phase 1a trial of SYX-5219 evaluates safety, tolerability and pharmacokinetics, showing dose-dependent reduction in serum CCL17/TARC

• SYX-5219 advances into Phase 1b trial in atopic dermatitis, with readout expected by year end

• Sitryx participates in Cantor's private company webinar series to discuss its immunometabolism platform

Clinical-stage biopharmaceutical company developing first- and potentially best-in-class oral immunometabolism therapies intended to deliver biologic-like efficacy with improved safety and tolerability, moving from symptom control toward lasting, functional cure in inflammatory disease.

• SYX-5219

  Oral pyruvate kinase M2 (PKM2) modulator; lead clinical program in Phase 1b for atopic dermatitis.

• Psoriasis program

  Pipeline program in psoriasis.

• Asthma program

  Pipeline program in asthma.

1. 1Pioneers in immunometabolism - Sitryxsitryx.com
2. 2About - Sitryxsitryx.com
3. 3Cantor Shares Takes from Private Company Webinar Series - Sitryxsitryx.com
4. 4Sitryx Therapeutics Limited (United Kingdom) - Wikidatawikidata.org